华熙生物
(688363)
| 流通市值：232.89亿 | | | 总市值：232.89亿 |
| 流通股本：4.82亿 | | | 总股本：4.82亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,874,744,443.18 | 2,810,742,396.15 | 1,360,531,915 | 6,075,923,853.74 |
| 营业收入 | 3,874,744,443.18 | 2,810,742,396.15 | 1,360,531,915 | 6,075,923,853.74 |
| 二、营业总成本 | 3,419,165,826.77 | 2,368,091,581.71 | 1,042,739,955.34 | 5,438,234,078.17 |
| 营业成本 | 1,010,187,630.31 | 716,281,088.32 | 330,181,652.26 | 1,621,027,890.22 |
| 税金及附加 | 49,073,723.5 | 34,522,584.09 | 15,043,523.89 | 67,100,887.26 |
| 销售费用 | 1,630,984,967.48 | 1,178,513,189.08 | 490,355,142.58 | 2,842,387,206.28 |
| 管理费用 | 422,950,678.62 | 246,465,617.88 | 116,094,685.69 | 492,166,284.58 |
| 研发费用 | 313,104,634.64 | 200,524,874.26 | 95,741,342.1 | 446,346,769.17 |
| 财务费用 | -7,135,807.78 | -8,215,771.92 | -4,676,391.18 | -30,794,959.34 |
| 其中:利息费用 | 1,647,871.59 | 1,398,303.07 | 1,290,729.41 | 6,230,423.38 |
| 其中:利息收入 | 12,241,765 | 10,036,986.99 | 5,985,622.41 | 38,456,118.58 |
| 加:公允价值变动收益 | 32,136.99 | 35,260.27 | - | 1,467,665.76 |
| 加:投资收益 | -4,995,868.91 | -3,069,192.67 | -1,591,342.57 | 1,327,375.89 |
| 资产处置收益 | -7,940.78 | - | - | -3,424,302.25 |
| 资产减值损失(新) | -18,153,627.1 | -21,810,081.99 | -7,135,537.86 | -54,403,392.42 |
| 信用减值损失(新) | -39,832,453 | -31,974,888.64 | -22,948,505.65 | -5,063,483.4 |
| 其他收益 | 43,503,891.72 | 30,447,567.39 | 14,202,539.34 | 130,791,911.44 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 436,124,755.33 | 416,279,478.8 | 300,319,112.92 | 708,385,550.59 |
| 加:营业外收入 | 2,313,821.26 | 1,813,838.57 | 545,158.16 | 2,865,147.21 |
| 减:营业外支出 | 1,869,466.61 | 681,426.66 | 259,602.73 | 9,528,235.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 436,569,109.98 | 417,411,890.71 | 300,604,668.35 | 701,722,462.64 |
| 减:所得税费用 | 77,519,223.85 | 76,907,679.27 | 57,217,016.03 | 118,980,429.13 |
| 六、净利润 | 359,049,886.13 | 340,504,211.44 | 243,387,652.32 | 582,742,033.51 |
| 持续经营净利润 | 359,049,886.13 | 340,504,211.44 | 243,387,652.32 | 582,742,033.51 |
| 归属于母公司股东的净利润 | 362,023,904.69 | 341,765,629.08 | 243,367,321.4 | 592,555,911.37 |
| 少数股东损益 | -2,974,018.56 | -1,261,417.64 | 20,330.92 | -9,813,877.86 |
| (一)基本每股收益 | 0.75 | 0.71 | 0.51 | 1.23 |
| (二)稀释每股收益 | 0.75 | 0.71 | 0.51 | 1.23 |
| 八、其他综合收益 | -1,856,452.6 | -10,234,829.2 | -9,119,542.06 | 28,665,320.95 |
| 归属于母公司股东的其他综合收益 | -1,856,452.6 | -10,234,829.2 | -9,119,542.06 | 28,665,320.95 |
| 九、综合收益总额 | 357,193,433.53 | 330,269,382.24 | 234,268,110.26 | 611,407,354.46 |
| 归属于母公司股东的综合收益总额 | 360,167,452.09 | 331,530,799.88 | 234,247,779.34 | 621,221,232.32 |
| 归属于少数股东的综合收益总额 | -2,974,018.56 | -1,261,417.64 | 20,330.92 | -9,813,877.86 |
| 公告日期 | 2024-10-31 | 2024-08-24 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |